Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference
07 Novembre 2007 - 10:00PM
PR Newswire (US)
WESTMINSTER, Colo., Nov. 7 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company
focused on the development and commercialization of small molecule
therapeutics for the treatment of cancer, today announced that the
Company will participate in the 2007 JMP Securities Healthcare
Focus Conference in Boston. The Company's presentation will take
place at 12 p.m. (Eastern) on Tuesday, November 13, 2007. There
will be a live webcast of the presentation, which will be
accessible through a link posted on the Allos website home page and
investor relations section. The webcast will be available for
replay on Allos' website through November 27, 2007. About Allos
Therapeutics, Inc. Allos Therapeutics is a biopharmaceutical
company focused on the development and commercialization of small
molecule therapeutics for the treatment of cancer. The Company's
lead product candidate, PDX (pralatrexate), is a novel antifolate
currently under evaluation in a pivotal Phase 2 (PROPEL) trial in
patients with relapsed or refractory peripheral T-cell lymphoma.
The PROPEL trial is being conducted under an agreement reached with
the U.S. Food and Drug Administration under its special protocol
assessment, or SPA process. The Company is also investigating PDX
in patients with non-small cell lung cancer and a range of other
lymphoma sub-types. The Company's other product candidate is RH1, a
targeted chemotherapeutic agent, for which the Company expects to
initiate a Phase 1 trial in patients with advanced solid tumors in
the fourth quarter of 2007. For additional information, please
visit the Company's website at http://www.allos.com/. Safe Harbor
Statement The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2006 and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
the presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
DATASOURCE: Allos Therapeutics, Inc. CONTACT: Derek Cole, Vice
President, Investor Relations of Allos Therapeutics, Inc.,
+1-720-540-5367, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Allos Therapeutics (MM)